This short presentation will help you understand how to run two different FISH tests on the same slide for the same patient. This is a very cost-effective and efficient method for running FISH panels.
In this webinar, attendees will learn the answers to some of our most commonly asked questions about probe and slide storage, slide making and processing, and analyzing FISH testing. A technologist who engages in the webinar should expect to leave with an understanding of proper storage of Empire Genomics probes, proper slide making and processing […]
“Wash Away Your Probe-lems” addresses all things FISH washing. Upon completing the webinar, technologists should have an understanding of the importance of FISH washing, how to make and store proper wash solutions, and techniques involved in FISH washing. Technologists should also come from this webinar with washing tips that can be incorporated into their lab […]
This webinar will cover all the links in the process of successful FISH testing. A technologist should understand sample shipping and quality, mixture of reagents for FISH protocols, FISH protocol adjustments based on lab, equipment necessary for successful FISH testing, calibration and maintenance of the equipment, scope filters for probe dyes, and storage of FISHed […]
01
Apr
Apr
Buffalo, New York – April 1, 2024 – Empire Genomics Corp has been awarded a national group purchasing agreement for Molecular Analyzers, Reagents with Premier, Inc. Effective 02/01/2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for FISH (Fluorescent in situ Hybridization) Probes. “Empire […]
Non-small-cell lung cancer (NSCLC) is a genetically heterogeneous disease. In approximately 2% of NSCLC cases, the primary oncogenic mutation is a chromosomal rearrangement involving ROS1 (ROS proto-oncogene 1), where one of many diverse gene partners fuses to the 3’ kinase domain of ROS1 and results in the constitutive activation of the ROS1 receptor tyrosine kinase. The ROS1-targeted tyrosine kinase inhibitor (TKI) entrectinib is an FDA-approved treatment for patients with these ROS1 fusions (ROS1+ NSCLC) and has dramatically improved patient outcomes.
Endometrial polyps (EMPs) are localized overgrowths of endometrial tissue composed of endometrial glands, stroma, and blood vessels. The reported prevalence of EMPs increases with age and ranges from 8-35%, depending on the population studied. EMPs are considered benign, with a risk of malignancy of around 3%.
Alzheimer’s disease (AD) is the most common form of dementia in older adults. Cerebral amyloid angiopathy (CAA), which is characterized by the deposition of β-amyloid (Aβ) peptides within cerebral blood vessels, co-occurs with AD to some extent in 85-95% of AD cases and is an independent contributor to AD dementia. Indeed, cerebrovascular dysfunction, possibly resulting from Aβ deposits, has been implicated in early AD pathogenesis, preceding neuronal damage.
In the broadest sense, cancer development is spurred by genetic abnormalities that result in oncogene activation and tumor suppressor gene inactivation. In multiple myeloma (MM), a hematological malignancy that affects plasma cells, the amplification of chromosome 1q and the deletion of chromosome 17p have both been shown to be related to disease progression and poor patient outcomes. Chromosome 1q contains several oncogenes including NEK2 (never in mitosis gene A-related kinase 2), which has been shown to promote tumor cell proliferation, metastasis, and drug resistance in MM and other cancer types.
The aggressive basal-like breast cancer (BLBC) subtype, which strongly correlates with triple-negative (ER- PR- HER2-) breast cancers, comprises 15-20% of all breast cancer cases and has a poor prognosis, largely resulting from a lack of a molecularly targeted treatment regimen. Loss of control of signaling pathways frequently triggers tumorigenesis, and molecules involved in these signaling pathways are frequent molecular treatment targets. However, the mechanisms of tumorigenesis in BLBCs have yet to be fully elucidated.